RYR2 and Alzheimer disease: We found that AD HiNs have a significantly larger somatic RyR-calcium response (24.4% ± 1.8% over baseline; n = 189) than non-AD HiNs (7.8% ± 1.4% over baseline; n = 125; F(2,318) = 24.38; p < 0.001), effects that were mitigated with dantrolene treatment in the AD neurons (2.5% ± 1.7% over baseline; n = 5; Figure 4A).